参考文献/References:
[1] OLIVER A L.Lung cancer:Epidemiology and screening[J].Surg Clin North Am,2022,102(3):335-344.
[2] ZHANG Y T,VACCARELLA S,MORGAN E,et al.Global variations in lung cancer incidence by histological subtype in 2020:A population-based study[J].Lancet Oncol,2023,24(11):1206-1218.
[3] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[4] 苏坤,徐培培.清金化痰汤加减联合化疗对晚期肺癌患者中医症状积分及血清CYFRA21-1水平的影响[J].陕西中医,2024,45(4):511-515.
[5] GHANBAR M I,SURESH K.Pulmonary toxicity of immune checkpoint immunotherapy[J].J Clin Invest,2024,134(2):e170503.
[6] WU Y L,DZIADZIUSZKO R,AHN J S,et al.Alectinib in resected ALK-Positive Non-Small-Cell lung cancer[J].N Engl J Med,2024,390(14):1265-1276.
[7] 刘晓菊,姚芮,杨学知,等.早期非小细胞肺癌胸腔镜下肺亚段切除术与肺段切除术治疗效果比较[J].陕西医学杂志,2024,53(8):1069-1072.
[8] LI C L,JIN W,ZHANG D W,et al.Clinical significance of microRNA-1180-3p for colorectal cancer and effect of its alteration on cell function[J].Bioengineered,2021,12(2):10491-10500.
[9] CHAI R,ZHOU C H,HU Z L,et al.Diagnostic predictability of serum miR-4793-3p and miR-1180-3p expression in community-acquired pneumonia[J].Biomark Med,2024,18(6):231-241.
[10] AISO T,UEDA M.5'ÃisomiR is the most abundant sequence of miRÃ1246,a candidate biomarker of lung cancer,in serum[J].Mol Med Rep,2023,27(4):92.
[11] 中华人民共和国国家卫生健康委员会.原发性肺癌诊疗规范(2018年版)[J].肿瘤综合治疗电子杂志,2019,5(3):100-120.
[12] 中华医学会呼吸病学分会间质性肺疾病学组,中国医师协会呼吸医师分会间质性肺疾病工作委员会.中国肺结节病诊断和治疗专家共识[J].中华结核和呼吸杂志,2019,42(9):685-693.
[13] CAO W B,TANG Q Y,ZENG J T,et al.A review of biomarkers and their clinical impact in resected early-stage non-small-cell lung cancer[J].Cancers(Basel),2023,15(18):4561.
[14] ZHANG J T,LIU S Y,GAO W,et al.Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer[J].Cancer Discov,2022,12(7):1690-1701.
[15] ZHANG K,QU J,DENG S,et al.Serum IL-24 combined with CA125 as screening and prognostic biomarkers for NSCLC[J].Cell Biol Int,2024,48(8):1160-1168.
[16] ZHOU Z H,ZHOU X G,JIANG Y J,et al.Clinical significance of miR-1180-3p in hepatocellular carcinoma:A study based on bioinformatics analysis and RT-qPCR validation[J].Sci Rep,2020,10(1):11573.
[17] 林映雪,崔海鹏,姚银辉,等.失巢凋亡相关miRNAs预测肝细胞癌预后的分析[J].现代肿瘤医学,2024,32(4):601-609.
[18] 孔令玉,朱天怡.微小RNA-1180在非小细胞肺癌中的表达及其临床意义[J].实用临床医药杂志,2022,26(3):76-80.
[19] 储祥健,曹海燕,戴美云.血清肿瘤标志物联合microRNA-1246检测对局部晚期非小细胞肺癌同步放化疗敏感性的评估价值[J].海军医学杂志,2023,44(12):1259-1263.
[20] 楚丽,要雪品,梁艳,等.MiR-1246对肺癌细胞放疗敏感性的调控及对放疗所致肺损伤的影响[J].重庆医学,2021,50(17):2900-2905,2911.
[21] 刘利,邓太兵,唐藜.血清CA125、AFP表达与NSCLC患者化疗效果的相关性[J].中国实验诊断学,2023,27(6):655-658.
[22] 杨波,陈洋,关静文,等.五项肿瘤标志物与非小细胞肺癌患者临床病理特征及预后的相关性研究[J].广州医科大学学报,2023,51(1):40-44.
[23] 范骏,魏可,骆金华,等.血清微小RNA-184、微小RNA-451a表达对Ⅰ-ⅡA期非小细胞肺癌根治术后复发转移的预测价值[J].实用临床医药杂志,2024,28(13):1-6.
[24] 严洁,王裕虎.血清微管解聚蛋白、CHI3L1与非小细胞肺癌患者肺癌根治术后复发转移的关系[J].检验医学与临床,2024,21(8):1054-1058.
[25] 郭爱霞,王珍,孙倩,等.CA72-4、CA15-3、AFP及NSE评估非小细胞肺癌患者术后预后的价值观察[J].实用癌症杂志,2023,38(3):422-426.
[26] 戴斌,曾颖鸥,乔弟,等.血清miR-1246、CXCL12和CXCR4水平预测非小细胞肺癌患者术后预后的效能[J].检验医学与临床,2023,20(10):1417-1421,1426.
相似文献/References:
[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(4):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(4):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(4):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(4):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(4):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(4):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(4):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]